Vaccine development has the potential to be accelerated by coupling tools such as systems
immunology analyses and controlled human infection models to define the protective …

Background RTS, S is the leading malaria vaccine candidate but only confers partial efficacy
against malaria in children. RTS, S is based on the major Plasmodium falciparum sporozoite …

After more than 50 years of intensive research and development, only one malaria vaccine
candidate,“RTS, S,” has progressed to Phase 3 clinical trials. Despite only partial efficacy …

Background Development of an effective vaccine against the pathogenic blood-stage
infection of human malaria has proved challenging, and no candidate vaccine has affected …

RTS, S is an advanced malaria vaccine candidate and confers significant protection against
Plasmodium falciparum infection in humans. Little is known about the molecular …

Naturally acquired immunity (NAI) to Plasmodium falciparum malaria is mainly mediated by
IgG antibodies but the subclasses, epitope targets and effector functions have not been …

Background Recent vaccine studies have shown that the magnitude of an antibody
response is often insufficient to explain efficacy, suggesting that characteristics regarding the …

Malaria-071, a controlled human malaria infection trial, demonstrated that administration of
three doses of RTS, S/AS01 malaria vaccine given at one-month intervals was inferior to a …

Malaria is a major cause of morbidity and mortality. Immunity is acquired but is suboptimal,
being slow to develop and incomplete. An inadequate understanding of natural immunity …

Abstract Development of a malaria vaccine remains a critical priority to decrease clinical
disease and mortality and facilitate eradication. Accordingly, RTS, S, a protein-subunit …